 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Medytox, which received the cancellation of the item license for botulinum toxin from the Ministry of Food and Drug Safety (MFDS), won the first trial of the administrative disposition cancellation lawsuit.
The Daejeon District Court (Daejeon District Court) Administration Department 3 on the 6th ruled in favor of the plaintiff, citing Medytox's claim in a lawsuit filed by Medytox against the Daejeon Food and Drug Administration for cancellation, including an order to suspend manufacturing and sales. Medytox's request to cancel the Ministry of Food and Drug Safety's cancellation of the item license was also accepted.
Earlier, the Ministry of Food and Drug Safety ordered the recall and disposal of these products on Oct. 19, 2020, saying that Medytox sold the company's botulinum toxin products without state shipping approval. This is because biological agents such as botulinum toxin agents believe that even licensed products should be inspected once again before they are distributed on the market.
Medytox says it has made so-called "indirect exports" to supply these products to trading companies to export them. It was determined that the product was not included in the national shipment approval list as it would not be distributed in Korea. In this regard, Medytox filed a lawsuit to cancel the KFDA's order to stop selling the product in question.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
